A 12-month, open-label, parallel-cohort study to evaluate the efficacy, safety and tolerability of Canakinumab in Kawasaki disease [Een 12 maanden durende, open-label, parallel-cohort studie naar de effectiviteit, veiligheid en werkzaamheid van de behandeling met Canakinumab in kinderen met de ziekte van Kawasaki]
Latest Information Update: 13 Mar 2020
At a glance
- Drugs Canakinumab (Primary) ; Canakinumab (Primary)
- Indications Mucocutaneous lymph node syndrome
- Focus Therapeutic Use
- Acronyms Kawakinumab
Most Recent Events
- 13 Mar 2020 Status changed from not stated to recruiting.
- 21 Aug 2019 New trial record